Wednesday, June 10, 2026

pharma Β· Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Β· IgA Nephropathy (IgAN) Β· VERA

Vera Therapeutics

Vera Therapeutics clinical programs β€” 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

4539 Metropolitan Ct, Frederick, Maryland 21704, US HQ
2018 Founded
9 Employees
Public company Type
VERA Β· NYSE Ticker
Company details
Status
Public
HQ
4539 Metropolitan Ct, Frederick, Maryland 21704, US
Founded
2018
Employees
9
Programs
25
Drugs
32
Patents
140
Intelligence Β· Clinical Programs

Vera Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Vera Therapeutics.

Vera Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CYP2C19 genotyping

    Vera Therapeutics

    Myocardial Infarction

    approved gene therapy completed

    1 trial
  2. Experimental: Hyperslim

    Vera Therapeutics

    Venous Thromboembolism (VTE)

    approved other active

    1 trial
  3. Peginterferon alfa-2a

    Vera Therapeutics

    Hepatitis B, Chronic

    approved small molecule active

    1 trial
  4. Pregabalin

    Vera Therapeutics

    Pain, Postoperative

    approved small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Vera Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.